Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review

American Journal of Emergency Medicine

Volumn 27, Issue 7, 2009, Pages 903.e1-903.e3

  Tu, Chung Ming ^a,b   Chu, Kai Ming ^b   Yang, Shin Ping ^b   Cheng, Shu Mung ^b   Wang, Wen been ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Tri Service General Medical Center   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; DRUG INDUCED DISEASE; FEMALE; HEART CATHETERIZATION; HUMAN; INTRADUCTAL CARCINOMA; LABORATORY TEST; LIVER METASTASIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 68349120461     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2008.11.012     Document Type: Article

References (11)

1. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
2. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
3. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
4. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
5. Slamon D., Eiermann W., Robert N., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94 (2005) S5 [abstr 1]
6. Yeon C.H., and Pegram M.D. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23 5 (2005) 391-409
7. Suter T.M., Cook-Bruns N., and Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13 3 (2004) 173-183
8. Wong S.F. Trastuzumab and cardiotoxicity: weighing the risks. Am J Health Syst Pharm 63 6 (2006) 525
9. Schneider J.W., Chang A.Y., and Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 29 3 Suppl 11 (2002) 22-28
10. Ewer M.S., Vooletich M.T., Durand J.-B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
11. Sliwkowski M.X., Lofgren J.A., Lewis G.D., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (1999) 60-70